Amgen’s shares reached a 52-week high of $441.56 on Thursday, extending a 55.4% gain over the past year as investors balanced robust financial performance with regulatory and valuation risks. The stock remains 1.9% below a $450 fair-value estimate, according to consensus estimates, while Piper Sandler’s recent price target increase to $457 implies limited near-term upside relative to current levels.
The biotech’s valuation metrics reflect its growth trajectory. The trailing price-to-earnings ratio stands at 27.4x, while the forward P/E is 19.1x. EV/EBITDA is 16.0x, and the dividend yield is 2.3%. Leverage remains elevated, with a debt-to-equity ratio of 490.3%, largely attributed to the $3.7 billion acquisition of Horizon Therapeutics in 2024.
Revenue has expanded from $25.98 billion in fiscal 2021 to a projected $36.75 billion in fiscal 2025, a 41.4% increase over four years. EBITDA has grown from $12.55 billion to $16.62 billion over the same period, while free cash flow has averaged approximately $8.6 billion annually over five years.
Pipeline developments offer both opportunities and challenges. The Phase 3 CROSSING trial for Tezspire in eosinophilic esophagitis met co-primary endpoints on August 26, 2026, positioning the drug for a potential expansion into a U.S. market of over 470,000 patients, half of whom remain inadequately controlled. MariTide, targeting obesity and diabetes, is viewed as a potential differentiator in the GLP-1 drug class due to its tolerability profile. However, regulatory scrutiny persists: the EU revoked approval for Tavneos and the UK suspended its use following concerns over unreliable trial data, while the FTC challenges Amgen’s patent acquisition for Enbrel on antitrust grounds.
Technical indicators suggest the stock is approaching overbought territory. The weekly Relative Strength Index (RSI) stands at 72.8, with the Stochastic RSI at 93.5, while the Average Directional Index (ADX) confirms a strong trend at 51.6. Daily MACD momentum remains bullish at 13.43. Support levels are identified at $436.71 and $430.57, with a potential pullback zone between $426 and $430. Resistance is seen at $447.28, followed by $451.71.
